Total Face Group Limited
|
|
- Jordan Baldric Hunt
- 5 years ago
- Views:
Transcription
1 Total Face Group Limited 2017 Half Year Results Presentation
2 Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position Cash Flow Performance Update Allergan & Zeltiq Summary and Outlook Our Market Segment TFG Partnerships Our Growth Strategy Our TFG Brand 2
3 H1 FY17 Results Highlights Revenue of $9.95 million up 233% on pcp (H1 FY16 $2.99 million) Clinic profit of $2.78 million up 360% on pcp (H1 FY16 $0.6 million) Net assets of $22.3m Balance sheet in good position with the ability to refinance up to $3.0 million of CoolSculpting machines to increase cash reserves Clinic operating profit margin up 40% to 28% on pcp (H1 FY16 20%) Achieved an operational EBITDA of $1.0 million (Margin of 10%) before acquisition and one off costs Positive cash flows from operations of $0.4 million against pcp negative cash flows from operations of $0.9 million Cash balance of $1.7m as at 31 December
4 H1 FY17 Highlights Successfully completed capital raising of $10.0 million (Jul 2016) Successfully completed the acquisitions of 5 clinics: (Jul 2016) COZmedics (3 clinics in QLD) Endless Solutions (Port Melbourne Vic) Facial Artistry (ACT) Signed three way supply agreement between TFG, Zeltiq & Lumenis for CoolSculpting equipment, consumables and co-op marketing support (Jul 2016) Acquire and successfully brought online an additional 17 CoolSculpting machines taking TFG s install base to 28 machines across all 4 regions (Aug Dec 2016) Opened our first Sydney greenfield site in Chatswood Chase shopping complex (Oct 2016) Opened skin solutions retail store in Prahran Victoria (Nov 2016) Successfully re-located peninsula clinic to larger purpose built clinic in Mornington (Aug 2016) Successfully launched our brand for good looks (Sep 2016) Signed strategic partnership with Business Chicks Australia opening up marketing opportunities to their 42,000+ female members 4
5 Millions Half Year Results Revenue Bridge $10 $9 $8 $7 $6 $5 $4 $3 $2 $1 $0 1H FY17 Revenue Contribution Revenue grew to $9.95 million up from pcp $2.99 million Heber Davis (Broadway Clinic NSW) remains TFG s largest clinic contributing $1.9 million for 1H FY17 COZmedics (3 QLD clinics) have integrated extremely well contributing $2.8 million 1H FY17 Organic growth of $0.5 million (~20%) reflects steady growth in CoolSculpting treatments across 1H FY17 5
6 Half Year Results Revenue Breakdown Dermal 27% H1 FY17 Revenue by Modality 1,000, , , ,000 1H FY17 Body Fat Reduction Revenue Growth Coolsculpting 10% Injectables 63% 200,000 0 Jul Aug Sep Oct Nov Dec 1H Cosmetic injectables and Skin Solutions combined contributed just under $9.0 million in revenue for 1H FY17 which was ahead of internal forecasts Coolscuplting contributed ~$1.0 million in revenue which was behind internal forecasts due to: Timing of bringing machines online Training of clinicians 6
7 Half Year Results Clinic Profitability HY17 HY16 Sales Revenue $ 9,952,200 $ 2,988,554 COGS $ 2,641,949 $ 630,380 Gross Profit $ 7,310,251 $ 2,358,174 Gross Profit Margin 73% Labour $ 3,592,520 $ 1,476,303 Facilities $ 935,415 $ 278,072 $ 4,527,935 $ 1,754,375 Clinic Profit $ 2,782,316 $ 603,799 Clinic Profit Margin 28% 20% Strong Clinic profitability margin of 28% against internal forecast margin of 25% reflects: Strong supply agreements across all consumables Stable facilities costs Stable clinic labour costs Expect clinic profit margins to stabilise around 25% Gross Profit margin of 73% within internal forecast range of 70-75% again reflecting our strong supply relationships 7
8 Half Year Results Profit & Loss Corporate Costs HY17 HY16 Labour $ 742,700 $ 388,209 Marketing $ 759,634 $ 127,486 Marketing Rebate ($ 375,000) - IT & Communications $ 168,978 $ 96,028 Consultants $ 134,464 $ 71,798 Insurance $ 102,968 $ 13,472 Occupancy $ 35,178 $ 48,507 Other $ 197,309 $ 123,035 Total Corporate Costs $ 1,766,231 $ 868,535 Operational EBITDA $ 1,016,085 ($ 264,736) EBITDA Margin 10% -9% Acquisition Costs $ 267,326 - Other one offs $ 101,475 - Statutory EBITDA $ 647,284 ($ 264,736) Margin 7% -9% Depreciation $ 675,308 $ 224,738 Interest $ 62,113 $ 73,196 Net Loss ($ 90,137) ($ 562,670) Increased labour includes state based clinic operations managers, new HR/Payroll manager, Directors fees ($65k) and increase in payroll tax ($137k) Marketing campaigns during 1H FY17 was supplemented by co-op marketing rebate received from Zeltiq IT & Communications correlates to increase in clinics and user numbers Acquisition costs relate to QLD state Govt. stamp duty on COZmedics acquisition & associated legal expenses Other one-offs relate to increased audit fees due subsequent events surrounding post 30 Jun business combinations Increase in Depreciation relates to increased investment in CoolSculpting machines 8
9 Half Year Results Financial Position 31 Dec 2016 $ June 2016 $ 000 Movement $ 000 Cash and cash equivalents 1,744 2,601 (857) Receivables Inventories 1, Prepayments and Deposits Current tax receivable Plant & Equipment 5,588 2,608 2,980 Intangible assets 21,311 8,460 12,851 Total Assets 31,138 15,303 15,835 Creditors and accruals 2,114 1, Deferred Consideration 1 5, ,359 Borrowings 1,219 1, Provisions Other liabilities Total Liabilities 8,867 3,976 4,891 Net Assets 22,271 11,327 10,944 Note 1 50% cash and 50% TFG Script Receivables of $373k includes $174k of marketing rebate from Zeltiq (received Feb 2017) Increase of inventories correlates to increase in number of clinics and expansion of CoolSculpting machines Plant and equipment up by $2.9m includes addition of 17 CoolSculpting machines Intangible assets includes $20m of Goodwill on acquisitions and $1m invested in development of TESSA Deferred consideration includes COZmedics ($3m), Facial Artistry ($1.2m) and Face Today & Rejuven8 ($0.8m) - All are payable as 50% cash and 50% shares in TFG Borrowings relates to finance lease liability on equipment 9
10 Half Year Results Cash Flow Performance Significant improvement in cash flow from operations over 1H FY17 H1 FY17 $ 000 H1 FY16 $ 000 Movement $ 000 Opening cash balance 2, ,229 Cash from operations 411 (920) 1,331 Cash used in investing (10,235) (34) (10,201) Cash provided by financing activities 8,966 4,424 4,542 Closing cash balance 1, ,167 Positive cash flow from operations at 64% of EBITDA and expected to continue to strengthen in line with revenue growth Investing cash outflows reflects significant acquisition activity and investment in leasehold improvements and TESSA: ~$7.0 million acquiring COZMedics, Endless Solutions, Facial Artistry $2.9 million on clinic equipment including an additional 17 CoolSculpting machines $300k on further development of our proprietary application TESSA $250k on clinic leasehold improvements and computer equipment 10
11 Operations Update Financial performance for 1H FY17 reflects a strong contribution from both the Cosmetic Injectables and Skin Solutions modalities CoolSculpting remains a key focus area with 40+ CoolEvents scheduled across calendar 2017 Strengthened the executive team through the appointment of Kerstin Grant (Head of Operations) and Kathryn Bran (Group Manager Facial Aesthetics) to position TFG for further organic and acquisitive growth Implemented TESSA in our Broadway (Heber Davis) clinic in Jan 2017 completing the rollout to all NSW clinics TFG now has 17 Treating Doctors, 1 Nurse Practitioner, 21 Registered nurses and 17 dermal clinicians Continue to invest in developing a strong and reputable industry-leading brand 11
12 Update Allergan & Zeltiq On 14 th February 2017 Dublin-based Allergan Plc (Allergan), led by its Chief Executive Brent Saunders, agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc. TFG views this acquisition as a positive reinforcement of our strategic decision to invest in the body fat reduction market and we feel strongly that it validates our decision to do so using the CoolSculpting technology TFG has a very strong relationship with both Allergan and Zeltiq which should help minimise any disruption as both parties work through completion activities Based on our knowledge of how Allergan grows market penetration across their other product and service lines, we see medium to long-term benefits in the Australian market and anticipate an even greater focus on increasing market awareness of the worlds leading non-invasive body fat reduction technology 12
13 Summary and Outlook TFG has achieved a great deal in 1H FY17: $10.0 million capital raise Added five new clinics via acquisition and now have a footprint across 4 regions on the eastern seaboard of Australia Became the second largest install base of CoolSculpting globally Achieved its maiden operational EDITDA of $1.0m Cash flows from operations turned positive Launched our brand for good looks Even though Jan-Jun is traditionally slower than Jul-Dec, we expect 2H FY17 to show growth across all levels, driven to a large extent through the expected increase in CoolSculpting revenue now that all 28 machines are operational with trained clinicians in place We continue to assess a number of further acquisitions and whilst TFG has not progressed discussions with potential acquisition targets to a point that would require TFG to make disclosure to the market in line with ASX listing rules, we do expect further acquisitions will be completed in 2H FY17 13
14 Our Market Segment TFG Targets the premium non-invasive treatment market Several important features distinguish non-invasive modalities from plastic surgery. Non-invasive treatments have lower risk of complication Less costly and are temporary in nature Treatments fade with time and require re-treatment 3-4 times per year creating reoccurring revenue streams which underwrites future business growth TFG has a strong focus on training with all clinics operating with highly qualified and trained doctors, registered nurses and dermal clinicians Our growth is anticipated to be unpinned by three strong and growing market segments. Anti-ageing Skin Solutions CoolSculpting 14
15 TFG Partnerships We have strengthened and developed our Brand which has resulted in an increased ability to negotiate and partner with significant national and international companies. Partnership with Lumenis and Zeltiq at a global level for consumables, capital equipment and co-operative marketing of CoolSculpting within Australia Business Chicks - As the Beauty Partner for Business Chicks in Australia, we have seen increased brand awareness, opportunities for event partnership and exposure to their 42,000+ female members As TFG continues to grow in size and develop a national footprint our discussions with large corporate groups continues to gain momentum with a number of discussion's underway with national organisations TFG is also in discussions with a number of key television personalities to become brand ambassadors 15
16 Our Growth Strategy Creation of an industry brand connecting to the emotion and not the treatment itself Further acquisitions with the objective to enhance our geographic presence, strengthen our clinical team further, and increase the treatments we deliver we believe in a world where compliments and acceptance can come naturally Continue to invest in our proprietary application TESSA to maintain clinical excellence, operational control and even greater insights to our clients Maintain market leadership in body fat reduction using the CoolSculpting technology to become the most successful, influential and respected organisation in the medical aesthetic market Further strengthen our relationships with industry suppliers at a global level 16
17 Our TFG Brand Total Face Group continues to invest in developing a strong and reputable, industry-leading Brand to connect with consumers on an emotional level and not the treatment(s) itself Our brand will evoke Passion Consumers refer more often to, and passionately about, a brand they know, like and trust Our brand will bring New Clients by focussing on our expertise, education, and experience accelerating awareness and enhancing our reputation Our brand will help us reach the right audience it is estimated that 19/20 people who want to participate currently do not. Our Brand helps us attract the right clients and is critical to us becoming the market leader Competitive Advantage Our Brand will help us stand out for the right reasons Brand synergies A quality Brand will assist in partnering with similar reputable Brands (eg Allergan, Zeltiq, Vogue and Business Chicks) 17
18 Disclaimer This presentation was not prepared for and should not be relied upon to provide all necessary information for investment decisions. Some of the information contained in this presentation contains forward-looking statements which may not directly or exclusively relate to historical facts. Although great care & diligence has been taken to ensure the accuracy of this presentation, Total Face Group Limited gives no warranties in relation to the statements and information contained herein and disclaims all liability arising from persons acting on the information and statements in this presentation. Due to the dynamics and changing risk profiles of investment markets, Total Face Group Limited reserves the right to change its opinion at any time. All investors are strongly advised to consult professional financial advisors whose role it is to provide professional financial advice, taking into account an individual investor s investment objectives, financial situations and particular needs 18
19 we believe in a world where compliments and acceptance can come naturally
For personal use only
Total Face Group Level 4, Bank House 11 19 Bank Place Melbourne 3000 www.totalfacegroup.com.au TOTAL FACE GROUP LTD 17th March 2016 Australian Securities Exchange Company Announcement Office Stock Exchange
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationOperational Efficiency:
Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationImproving the lives of people with neurological conditions. Annual General Meeting Neurotech International Limited (ASX: NTI) November 2017
Improving the lives of people with neurological conditions Annual General Meeting Neurotech International Limited (ASX: NTI) November 2017 Neurotech Overview Medical device company, focussed on the development
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationFor personal use only
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationInvestor Relations 1Q 2017
Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA
More informationEUROZ INVESTOR CONFERENCE
Cedar Woods Properties Limited EUROZ INVESTOR CONFERENCE 14 March 2017 Cedar Woods strategy Cedar Woods Presentation 2 To grow and develop our national project portfolio, diversified by: geography product
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationEllex Medical Lasers (ASX: ELX)
Ellex Medical Lasers (ASX: ELX) Investor Presentation March 2012 Tom Spurling, Chief Executive 82 Gilbert Street, Adelaide, Australia Phone +61 8 8104 5200 tspurling@ellex.com Ellex in a snapshot Global
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationFor personal use only
ASX ANNOUNCEMENT 22 NOVEMBER 2017 AGM ADDRESSES FROM THE CHAIRMAN & CEO 22 November 2017 Cann Group Limited (ASX: CAN) is pleased to provide the following addresses to be delivered by its Chairman Allan
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationASX Announcement 22 June 2017
ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationInvestor Presentation
Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of
More informationQUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010
QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationIntroductory Presentation
Introductory Presentation WEEK 6 WEEK WEEK 1 2 WEEK 5 WEEK 3-4 STRUCTURED HORIZON WELCOME TO THE FAMILY FRANCHISE AGREEMENT DELIVERY PERSONALIZED FRANCHISE AGREEMENTS DELIVERED DAY OF DISCOVERY MEET THE
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationCochlear Limited 2017 Annual General Meeting Chairman s Address
Cochlear Limited 2017 Annual General Meeting Chairman s Address 17 October 2017 Rick Holliday-Smith Chairman Ladies and gentlemen Financial results Cochlear reported a record net profit of $224 million,
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationGrupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012
Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market September 28th, 2012 All rights reserved 2012 Disclaimer This presentation may contain forward-looking statements.
More informationInvestor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free
Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars
More information1Q 2009 Results Presentation. 12 May 2009
1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationEllex Medical Lasers (ASX: ELX)
Ellex Medical Lasers (ASX: ELX) Investor Presentation for Year End 30 June 2012 (prepared 31 August 2012) Tom Spurling, Chief Executive 82 Gilbert Street, Adelaide, Australia Phone +61 8 8104 5200 tspurling@ellex.com
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationAnnual General Meeting 25 October Cogstate Ltd. All rights reserved.
Annual General Meeting 25 October 2017 2017 Cogstate Ltd. All rights reserved. Board of Directors Audit, Risk & Compliance Committee Remuneration & Nomination Committee Martyn Myer Non-Exec Chairman Yes
More informationCorporate Presentation October New growth cycle and value innovation
Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationLUZHOU BIO-CHEM TECHNOLOGY LIMITED. 1HFY2006 Results Briefing. August 15, 2006
LUZHOU BIO-CHEM TECHNOLOGY LIMITED 1HFY2006 Results Briefing August 15, 2006 Agenda Who We Are A Growing Industry Financial Review Corporate Updates Future Plans Q&A 2 Who We Are Leading Corn Sweetener
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationInvestor Presentation September Cogstate Ltd. All rights reserved.
Investor Presentation September 2017 2017 Cogstate Ltd. All rights reserved. We believe that brain health is profoundly important to quality of life and should be easier to measure. That s why we so passionately
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More information2017 Annual General Meeting
Cedar Woods Presentation 1 Cedar Woods Properties Limited 2017 Annual General Meeting 9 November 2017 Cedar Woods Presentation 2 Agenda 1 Chairman s Address Mr William G Hames 2 Managing Director s Review
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationVery good Q3 contribution from Vegetable Juices Inc.
2014 nine-month sales (1 st January to 30 September 2014) Very good Q3 contribution from Vegetable Juices Inc. Worldwide economic environment still adverse Sustained growth by Food & Beverage Press release
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationTruScreen Annual Meeting
TruScreen Annual Meeting September 2018 Shareholders Address FY18 ANNUAL MEETING SHAREHOLDERS ADDRESS 27 SEPTEMBER 2018 INTRODUCTION Welcome to the 2018 AGM. FY18 HIGHLIGHTS 2018 was a year of significance
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationMental Toronto Hydro
Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More information1Q2005. Hera Group presentation
1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More information